Liposarcoma Pipeline Analysis Report 2025

As a soft tissue sarcoma, liposarcoma is an uncommon malignancy that starts in fat cells. It usually appears in the abdomen, limbs, or other places with adipose tissue. Location-specific symptoms can include lumps, discomfort, or swelling. Well-differentiated, myxoid, round-cell, dedifferentiated, and pleomorphic liposarcomas are common varieties. Surgery is typically used for treatment, though it can occasionally be paired with chemotherapy or radiation. Genetic disorders and previous radiation exposure are risk factors. The liposarcoma pipeline analysis by Expert Market Research focuses on various treatment options for this disease.

Report Coverage

The Liposarcoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into liposarcoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Liposarcoma therapeutics. The liposarcoma report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The liposarcoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with liposarcoma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to liposarcoma.

Liposarcoma Pipeline Outlook

There are genetic and histological differences among the subtypes of liposarcoma in its pathogenesis. The retroperitoneum is frequently the site of well-differentiated liposarcomas, which are linked to chromosomal amplifications in region 12q13-15 involving oncogenes such as MDM2 and CDK4. Dedifferentiated liposarcomas can arise from scratch and are more aggressive. Whereas pleomorphic liposarcomas entail mutations in tumor suppressors such p53, myxoid liposarcomas have gene fusions (DDIT3-FUS) that promote cell proliferation. Different growth patterns and recurrence risks are displayed by each subtype.

Surgery is the main treatment for liposarcoma, with the goal of removing the tumor with clear margins to avoid recurrence. Radiation therapy can be used to reduce the tumor before surgery or to get rid of any remaining cancer cells following surgery. Although its efficacy varies by subtype, chemotherapy is taken into consideration in situations that are aggressive or metastatic. Targeted medicines like as immunotherapy and CDK4/6 inhibitors are examples of advanced treatments, especially for genetic profiles. Clinical trials investigate innovative strategies.

Liposarcoma Epidemiology

With a global prevalence of roughly 0.25 cases per 100,000 people, liposarcoma is the second most prevalent soft tissue sarcoma in adults. With age-standardized rates of 6.2 cases per million people, liposarcomas make up 10% of soft tissue sarcomas in England. The incidence is twice as high in males as in females, and it peaks between the ages of 75 and 85. Across all ethnic groups, middle-aged and elderly persons are the most affected.

Liposarcoma - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of liposarcoma drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

By Route of Administration

• Oral
• Parenteral
• Others

Liposarcoma - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total liposarcoma clinical trials.

In the liposarcoma pipeline, maximum candidates are concentrated in Phase II with 56% of the projects followed by Phase I with 25% of candidates. The rest 19% of candidates are in Phase III. Thus, demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.

Liposarcoma - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the liposarcoma pipeline analysis include monoclonal antibodies, peptides, small molecules and gene therapy. The liposarcoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Liposarcoma.

Liposarcoma Clinical Trials - Key Players

The report for the liposarcoma pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in liposarcoma clinical trials:

• Boehringer Ingelheim
• Adaptimmune
• Salarius Pharmaceuticals, LLC

Liposarcoma - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for liposarcoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of liposarcoma drug candidates.

Drug: Brigimadlin

Boehringer Ingelheim developed the experimental oral MDM2-p53 antagonist brigimadlin (BI 907828). By restoring p53 activity, it targets cancers with MDM2 amplification and wild-type TP53, resulting in apoptosis and cell cycle arrest. The drug is presently in Phase 3 clinical trials for several tumors, such as glioblastoma, biliary tract cancer, and dedifferentiated liposarcoma. Its potential anticancer activity and tolerable safety profile have been shown in preliminary studies.

Drug: Seclidemstat

Seclidemstat, developed by Salarius Pharmaceuticals, is an oral LSD1 inhibitor under investigation in a Phase 1/2 trial for treating relapsed or refractory Ewing sarcoma and related sarcomas, including myxoid liposarcoma. The study comprises three arms; one combining seclidemstat with chemotherapy for Ewing sarcoma, and two evaluating it as a single agent in myxoid liposarcoma and FET-rearranged sarcomas. Interim results indicate disease control in some patients. Salarius is collaborating with the FDA to analyze the data and determine the appropriate path forward.

Key Questions Answered in the Liposarcoma Pipeline Analysis Report

• Which companies/institutions are leading the liposarcoma drug development?
• What is the efficacy and safety profile of liposarcoma pipeline drugs?
• Which company is leading the liposarcoma pipeline development activities?
• What is the current liposarcoma commercial assessment?
• What are the opportunities and challenges present in the liposarcoma pipeline landscape?
• Which company is conducting major trials for liposarcoma drugs?
• Which companies/institutions are involved in liposarcoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in liposarcoma?

This product will be delivered within 3-5 business days.